Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
LP-300 Phase 2 Results Expected
LP-300 • Adenocarcinoma of Lung
Target Indication
Adenocarcinoma of Lung
Clinical Trial
Last updated: 12/4/2025
LTRN
Lantern Pharma Inc.